

Stuart J Knechtle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3173592/publications.pdf>

Version: 2024-02-01

311
papers

16,669
citations

14614

66
h-index

19690

117
g-index

463
all docs

463
docs citations

463
times ranked

10973
citing authors

#	ARTICLE	IF	CITATIONS
1	RISK FACTORS FOR PRIMARY DYSFUNCTION AFTER LIVER TRANSPLANTATION—A MULTIVARIATE ANALYSIS. <i>Transplantation</i> , 1993, 55, 807-813.	0.5	937
2	CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 8789-8794.	3.3	905
3	Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. <i>Nature Medicine</i> , 1999, 5, 686-693.	15.2	801
4	2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. <i>American Journal of Transplantation</i> , 2016, 16, 2816-2835.	2.6	451
5	Campath-1H Induction Plus Rapamycin Monotherapy for Renal Transplantation: Results of a Pilot Study. <i>American Journal of Transplantation</i> , 2003, 3, 722-730.	2.6	360
6	THE PREDICTIVE VALUE OF DONOR LIVER BIOPSIES FOR THE DEVELOPMENT OF PRIMARY NONFUNCTION AFTER ORTHOTOPIC LIVER TRANSPLANTATION. <i>Transplantation</i> , 1991, 51, 157-163.	0.5	346
7	Donation After Cardiac Death. <i>Annals of Surgery</i> , 2005, 242, 724-731.	2.1	342
8	Urinary-Cell mRNA Profile and Acute Cellular Rejection in Kidney Allografts. <i>New England Journal of Medicine</i> , 2013, 369, 20-31.	13.9	312
9	Experience With 500 Simultaneous Pancreas-Kidney Transplants. <i>Annals of Surgery</i> , 1998, 228, 284-296.	2.1	275
10	RESULTS OF THE DOUBLE-BLIND, RANDOMIZED, MULTICENTER, PHASE III CLINICAL TRIAL OF THYMOGLOBULIN VERSUS ATGAM IN THE TREATMENT OF ACUTE GRAFT REJECTION EPISODES AFTER RENAL TRANSPLANTATION ^{1,2} . <i>Transplantation</i> , 1998, 66, 29-37.	0.5	273
11	Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. <i>Lancet</i> , The, 2020, 395, 1627-1639.	6.3	266
12	Pneumatosis Intestinalis. <i>Annals of Surgery</i> , 1990, 212, 160-165.	2.1	205
13	Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. <i>American Journal of Transplantation</i> , 2018, 18, 1604-1614.	2.6	205
14	FN18-CRM9 IMMUNOTOXIN PROMOTES TOLERANCE IN PRIMATE RENAL ALLOGRAFTS ¹ . <i>Transplantation</i> , 1997, 63, 1-6.	0.5	196
15	Dissociation of Depletional Induction and Posttransplant Lymphoproliferative Disease in Kidney Recipients Treated With Alemtuzumab. <i>American Journal of Transplantation</i> , 2007, 7, 2619-2625.	2.6	194
16	SUCCESSFUL EXTRARENAL TRANSPLANTATION FROM NON-HEART-BEATING DONORS. <i>Transplantation</i> , 1995, 59, 977-982.	0.5	190
17	Expression of Naked Plasmid DNA Injected into the Afferent and Efferent Vessels of Rodent and Dog Livers. <i>Human Gene Therapy</i> , 1997, 8, 1763-1772.	1.4	186
18	β ₁ -Adrenergic effects and liver regeneration. <i>Hepatology</i> , 1987, 7, 1189-1194.	3.6	184

#	ARTICLE	IF	CITATIONS
19	The Role of Donor-Specific HLA Alloantibodies in Liver Transplantation. American Journal of Transplantation, 2014, 14, 779-787.	2.6	182
20	Liver transplantation from controlled non-heart-beating donors. Surgery, 2000, 128, 579-588.	1.0	177
21	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantation Society Working Group. Transplantation, 2020, 104, 911-922.	0.5	172
22	CD4+CD25+FOXP3+ Regulatory T Cells Increase De Novo in Kidney Transplant Patients After Immunodepletion with Campath-1H. American Journal of Transplantation, 2008, 8, 793-802.	2.6	158
23	Costimulation Blockade Alters Germinal Center Responses and Prevents Antibody-Mediated Rejection. American Journal of Transplantation, 2014, 14, 59-69.	2.6	157
24	Elevation of CXCR3-Binding Chemokines in Urine Indicates Acute Renal-Allograft Dysfunction. American Journal of Transplantation, 2004, 4, 432-437.	2.6	156
25	DETERMINANTS OF GRAFT SURVIVAL AFTER RENAL TRANSPLANTATION ¹ . Transplantation, 1996, 61, 1581-1586.	0.5	153
26	Donation After Cardiac Death: The University of Wisconsin Experience with Renal Transplantation. American Journal of Transplantation, 2004, 4, 1490-1494.	2.6	152
27	Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery, 2004, 136, 754-760.	1.0	139
28	A New Look at Blockade of T-cell Costimulation: A Therapeutic Strategy for Long-term Maintenance Immunosuppression. American Journal of Transplantation, 2006, 6, 876-883.	2.6	135
29	The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transplant International, 2006, 19, 705-714.	0.8	131
30	Simultaneous Pancreas-Kidney Transplantation and Living Related Donor Renal Transplantation in Patients With Diabetes: Is There a Difference in Survival?. Annals of Surgery, 2000, 231, 417-423.	2.1	122
31	STUDIES OF PEDIATRIC LIVER TRANSPLANTATION (SPLIT): YEAR 2000 OUTCOMES. Transplantation, 2001, 72, 463-476.	0.5	119
32	LONG-TERM RESULTS OF LIVER TRANSPLANTATION IN PATIENTS 60 YEARS OF AGE AND OLDER ¹² . Transplantation, 2000, 70, 780-783.	0.5	117
33	Urological Complications in 210 Consecutive Simultaneous Pancreas-Kidney Transplants with Bladder Drainage. Annals of Surgery, 1993, 218, 561-570.	2.1	116
34	RETRANSPLANTATION OF THE LIVER—A SEVEN-YEAR EXPERIENCE. Transplantation, 1993, 55, 1083-1086.	0.5	110
35	The Use of UW Solution in Clinical Transplantation A 4-year Experience. Annals of Surgery, 1992, 215, 579-585.	2.1	104
36	Underutilization of pancreas donors. Transplantation, 2003, 75, 1271-1276.	0.5	103

#	ARTICLE	IF	CITATIONS
37	Experience With 100 Consecutive Simultaneous Kidney-Pancreas Transplants With Bladder Drainage. <i>Annals of Surgery</i> , 1991, 214, 703-711.	2.1	96
38	POSTTRANSPLANT INFECTION IN ENTERIC VERSUS BLADDER-DRAINED SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANT RECIPIENTS ¹ . <i>Transplantation</i> , 1998, 66, 1746-1750.	0.5	96
39	Relationships between sclerosing cholangitis, inflammatory bowel disease, and cancer in patients undergoing liver transplantation. <i>Surgery</i> , 1995, 118, 615-620.	1.0	92
40	Donor-Directed MHC Class I Antibody Is Preferentially Cleared from Sensitized Recipients of Combined Liver/Kidney Transplants. <i>American Journal of Transplantation</i> , 2011, 11, 841-847.	2.6	92
41	OBESITY AS A RISK FACTOR FOLLOWING RENAL TRANSPLANTATION ¹ . <i>Transplantation</i> , 1995, 59, 631-647.	0.5	91
42	Living Related and Unrelated Donors for Kidney Transplantation A 28-Year Experience. <i>Annals of Surgery</i> , 1995, 222, 353-364.	2.1	91
43	Simultaneous Pancreas-Kidney Transplantation From Donation After Cardiac Death. <i>Annals of Surgery</i> , 2005, 242, 716-723.	2.1	89
44	BAFF Is Increased in Renal Transplant Patients Following Treatment with Alemtuzumab. <i>American Journal of Transplantation</i> , 2009, 9, 1835-1845.	2.6	88
45	Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. <i>Hepatology</i> , 2013, 57, 708-715.	3.6	88
46	Longitudinal Studies of a B Cellâ€œDerived Signature of Tolerance in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2015, 15, 2908-2920.	2.6	87
47	Campath-1H Use in Pediatric Renal Transplantation. <i>American Journal of Transplantation</i> , 2005, 5, 1569-1573.	2.6	85
48	Liver transplantation for HELLP syndrome. <i>Liver Transplantation</i> , 2005, 11, 224-228.	1.3	85
49	Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1206-1219.	3.0	85
50	T-lymphocyte Alloresponses of Campath-1H-Treated Kidney Transplant Patients. <i>Transplantation</i> , 2006, 81, 81-87.	0.5	83
51	Macrophages Driven to a Novel State of Activation Have Anti-Inflammatory Properties in Mice. <i>Journal of Immunology</i> , 2008, 180, 335-349.	0.4	80
52	HEPATIC TRANSPLANTATION INTO SENSITIZED RECIPIENTS. <i>Transplantation</i> , 1987, 43, 8-12.	0.5	79
53	Living unrelated renal donation: The University of Wisconsin experience. <i>Surgery</i> , 1998, 124, 604-611.	1.0	79
54	Noninvasive Detection of Acute and Chronic Injuries in Human Renal Transplant by Elevation of Multiple Cytokines/Chemokines in Urine. <i>Transplantation</i> , 2009, 87, 1814-1820.	0.5	77

#	ARTICLE	IF	CITATIONS
55	Metastable Tolerance to Rhesus Monkey Renal Transplants Is Correlated with Allograft TGF- β 1+CD4+T Regulatory Cell Infiltrates. <i>Journal of Immunology</i> , 2004, 172, 5753-5764.	0.4	76
56	Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model. <i>Transplantation</i> , 2004, 77, 914-920.	0.5	74
57	Unique Aspects of Rejection and Tolerance in Liver Transplantation. <i>Seminars in Liver Disease</i> , 2009, 29, 091-101.	1.8	73
58	Hypoxia of the growing liver accelerates regeneration. <i>Surgery</i> , 2017, 161, 666-679.	1.0	73
59	A STUDY COMPARING MYCOPHENOLATE MOFETIL TO AZATHIOPRINE IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION. <i>Transplantation</i> , 1998, 66, 1751-1759.	0.5	72
60	THE EFFECT OF DONOR AGE, RECIPIENT AGE, AND HLA MATCH ON IMMUNOLOGIC GRAFT SURVIVAL IN CADAVER RENAL TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1992, 53, 55-58.	0.5	71
61	Infected Bilomas in Liver Transplant Recipients, Incidence, Risk Factors and Implications for Prevention. <i>American Journal of Transplantation</i> , 2004, 4, 574-582.	2.6	71
62	Identification of new Mamu-DRB alleles using DGGE and direct sequencing. <i>Immunogenetics</i> , 1997, 45, 171-179.	1.2	69
63	Peripheral vascular disease and renal transplant artery stenosis: a reappraisal of transplant renovascular disease. <i>Clinical Transplantation</i> , 1999, 13, 349-355.	0.8	69
64	Calcineurin Inhibitor Withdrawal After Renal Transplantation with Alemtuzumab: Clinical Outcomes and Effect on T-Regulatory Cells. <i>American Journal of Transplantation</i> , 2008, 8, 1529-1536.	2.6	69
65	Early and Limited Use of Tacrolimus to Avoid Rejection in an Alemtuzumab and Sirolimus Regimen for Kidney Transplantation: Clinical Results and Immune Monitoring. <i>American Journal of Transplantation</i> , 2009, 9, 1087-1098.	2.6	67
66	Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1991-1996.	3.0	67
67	Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. <i>Transplant International</i> , 2006, 19, 885-892.	0.8	66
68	THE INFLUENCE OF NATIVE NEPHRECTOMY ON THE INCIDENCE OF RECURRENT DISEASE FOLLOWING RENAL TRANSPLANTATION FOR PRIMARY GLOMERULONEPHRITIS. <i>Transplantation</i> , 1996, 61, 228-234.	0.5	66
69	ORTHOTOPIC LIVER TRANSPLANTATION IN PATIENTS 60 YEARS OF AGE AND OLDER. <i>Transplantation</i> , 1991, 51, 431-432.	0.5	65
70	Primate renal transplants using immunotoxin. <i>Surgery</i> , 1998, 124, 438-447.	1.0	65
71	Induction immunosuppression in liver transplantation: a review. <i>Transplant International</i> , 2013, 26, 673-683.	0.8	63
72	Donor Factors Affecting Outcome After Pancreas Transplantation. <i>Transplantation Proceedings</i> , 1998, 30, 276-277.	0.3	61

#	ARTICLE	IF	CITATIONS
73	Dual targeting: Combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients. <i>American Journal of Transplantation</i> , 2019, 19, 724-736.	2.6	61
74	Developmental Exposure to Noninherited Maternal Antigens Induces CD4+T Regulatory Cells: Relevance to Mechanism of Heart Allograft Tolerance. <i>Journal of Immunology</i> , 2007, 179, 6749-6761.	0.4	59
75	Liver transplantation in pediatric patients: Twenty years of experience at the University of Wisconsin. <i>Pediatric Transplantation</i> , 2007, 11, 661-670.	0.5	59
76	Urine Osteoprotegerin and Monocyte Chemoattractant Protein-1 in Lupus Nephritis. <i>Journal of Rheumatology</i> , 2009, 36, 2224-2230.	1.0	59
77	Human CD4+CD25 ^{low} Adaptive T Regulatory Cells Suppress Delayed-Type Hypersensitivity during Transplant Tolerance. <i>Journal of Immunology</i> , 2007, 178, 3983-3995.	0.4	58
78	Tolerogenic therapies in transplantation. <i>Frontiers in Immunology</i> , 2012, 3, 198.	2.2	58
79	Laparoscopic vs Open Right Hepatectomy: A Value-Based Analysis. <i>Journal of the American College of Surgeons</i> , 2014, 218, 929-939.	0.2	58
80	Urine Metabolite Profiles Predictive of Human Kidney Allograft Status. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 626-636.	3.0	58
81	Infant pediatric liver transplantation results equal those for older pediatric patients. <i>Journal of Pediatric Surgery</i> , 1998, 33, 20-23.	0.8	57
82	INDUCTION OF SPECIFIC TOLERANCE BY INTRATHYMIC INJECTION OF RECIPIENT MUSCLE CELLS TRANSFECTED WITH DONOR CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX. <i>Transplantation</i> , 1994, 57, 990-996.	0.5	56
83	OBESITY AS A RISK FACTOR FOLLOWING RENAL TRANSPLANTATION ¹ . <i>Transplantation</i> , 1995, 59, 631-633.	0.5	56
84	Risk factors for renal allograft loss in patients with systemic lupus erythematosus. <i>Kidney International</i> , 1996, 49, 512-517.	2.6	56
85	Neutralizing BAFF/APRIL With Atacicept Prevents Early DSA Formation and AMR Development in T Cell Depletion Induced Nonhuman Primate AMR Model. <i>American Journal of Transplantation</i> , 2015, 15, 815-822.	2.6	56
86	XENOGRAFT SURVIVAL IN TWO SPECIES COMBINATIONS USING TOTAL-LYMPHOID IRRADIATION AND CYCLOSPORINE. <i>Transplantation</i> , 1987, 43, 173-175.	0.5	55
87	Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical living-related, and living-unrelated grafts ¹ . <i>Transplantation</i> , 2003, 75, 1677-1682.	0.5	51
88	Hepatocellular Carcinoma Lesion Characterization: Single-Institution Clinical Performance Review of Multiphase Gadolinium-enhanced MR Imaging—Comparison to Prior Same-Center Results after MR Systems Improvements. <i>Radiology</i> , 2011, 261, 824-833.	3.6	51
89	Racial and socioeconomic disparities in pediatric and young adult liver transplant outcomes. <i>Liver Transplantation</i> , 2014, 20, 100-115.	1.3	51
90	Open-label prospective study of the safety and efficacy of glass-bead-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis. <i>Cancer</i> , 2015, 121, 2164-2174.	2.0	51

#	ARTICLE	IF	CITATIONS
91	Crosstalk Between T and B Cells in the Germinal Center After Transplantation. <i>Transplantation</i> , 2017, 101, 704-712.	0.5	51
92	Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2399-2411.	3.0	51
93	Monitoring of kidney and simultaneous pancreas-kidney transplantation rejection by release of donor-specific, soluble HLA class I. <i>Human Immunology</i> , 1994, 40, 191-201.	1.2	50
94	SPLIT TOLERANCE INDUCED BY IMMUNOTOXIN IN A RHESUS KIDNEY ALLOGRAFT MODEL1. <i>Transplantation</i> , 1997, 63, 1339-1345.	0.5	50
95	Simultaneous Pancreas-Kidney (SPK) Transplantation from Controlled Non-Heart-Beating Donors (NHBDs). <i>Cell Transplantation</i> , 2000, 9, 889-893.	1.2	49
96	Superior Long-Term Results of Simultaneous Pancreas-Kidney Transplantation from Pediatric Donors. <i>American Journal of Transplantation</i> , 2004, 4, 2093-2101.	2.6	49
97	Identification of Potential Cytokine Pathways for Therapeutic Intervention in Murine Primary Biliary Cirrhosis. <i>PLoS ONE</i> , 2013, 8, e74225.	1.1	49
98	ANALYSIS OF PRIMATE RENAL ALLOGRAFTS AFTER T-CELL DEPLETION WITH ANTI-CD3-CRM91,2. <i>Transplantation</i> , 1998, 66, 5-13.	0.5	49
99	The Glucagon-Like Peptide-1 Receptor Agonist Exendin 4 Has a Protective Role in Ischemic Injury of Lean and Steatotic Liver by Inhibiting Cell Death and Stimulating Lipolysis. <i>American Journal of Pathology</i> , 2012, 181, 1693-1701.	1.9	48
100	Correlation Between Human Leukocyte Antigen Antibody Production and Serum Creatinine in Patients Receiving Sirolimus Monotherapy after Campath-1H Induction. <i>Transplantation</i> , 2004, 78, 919-924.	0.5	47
101	Infected Bilomas in Liver Transplant Recipients: Clinical Features, Optimal Management, and Risk Factors for Mortality. <i>Clinical Infectious Diseases</i> , 2004, 39, 517-525.	2.9	46
102	Alemtuzumab Induction and Antibody-Mediated Kidney Rejection After Simultaneous Pancreas-Kidney Transplantation. <i>Transplantation</i> , 2009, 87, 125-132.	0.5	46
103	Comparison between liver transplantation and resection for hilar cholangiocarcinoma: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0220527.	1.1	46
104	CXCR3-mediated T-cell chemotaxis involves ZAP-70 and is regulated by signalling through the T-cell receptor. <i>Immunology</i> , 2007, 120, 467-485.	2.0	45
105	ILIAC ARTERY PSEUDOANEURYSM FOLLOWING RENAL TRANSPLANTATION PRESENTING AS LUMBOSACRAL PLEXOPATHY. <i>Transplantation</i> , 1999, 67, 1077-1078.	0.5	45
106	A Comparison of Alemtuzumab with Basiliximab Induction in Simultaneous Pancreas-Kidney Transplantation. <i>American Journal of Transplantation</i> , 2008, 8, 1702-1710.	2.6	43
107	The INTUIT Study: Investigating Neuroinflammation Underlying Postoperative Cognitive Dysfunction. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 794-798.	1.3	43
108	Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 66, 7-15.	0.8	42

#	ARTICLE	IF	CITATIONS
109	Tolerance and near-tolerance strategies in monkeys and their application to human renal transplantation. <i>Immunological Reviews</i> , 2001, 183, 205-213.	2.8	41
110	Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients. <i>Pediatric Transplantation</i> , 2004, 8, 106-112.	0.5	41
111	Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. <i>Clinical and Experimental Immunology</i> , 2013, 174, 364-371.	1.1	41
112	Anomalous biliary ducts associated with duodenal atresia. <i>Journal of Pediatric Surgery</i> , 1990, 25, 1266-1269.	0.8	40
113	Textbook Outcomes in Liver Transplantation. <i>World Journal of Surgery</i> , 2020, 44, 3470-3477.	0.8	40
114	ADENOVIRUS-MEDIATED GENE TRANSFER INTO RAT CARDIAC ALLOGRAFTS. <i>Transplantation</i> , 1996, 61, 1726-1729.	0.5	40
115	Liver transplantation as definitive therapy for complications after arterial embolization for hepatic manifestations of hereditary hemorrhagic telangiectasia. <i>Liver Transplantation</i> , 1998, 4, 483-490.	1.9	39
116	Successful desensitization with proteasome inhibition and costimulation blockade in sensitized nonhuman primates. <i>Blood Advances</i> , 2017, 1, 2115-2119.	2.5	39
117	Risk factors and outcomes in post-liver transplantation bile duct stones and casts: A case-control study. <i>Liver Transplantation</i> , 2008, 14, 1461-1465.	1.3	38
118	SUCCESSFUL CONVERSION FROM CONVENTIONAL IMMUNOSUPPRESSION TO ANTI-CD154 MONOCLONAL ANTIBODY COSTIMULATORY MOLECULE BLOCKADE IN RHESUS RENAL ALLOGRAFT RECIPIENTS ^{1,2} . <i>Transplantation</i> , 2001, 72, 587-597.	0.5	38
119	Immunotoxin-treated rhesus monkeys: a model for renal allograft chronic rejection ¹ . <i>Transplantation</i> , 2003, 76, 524-530.	0.5	37
120	Overcoming Chronic Rejection—Can it B?. <i>Transplantation</i> , 2009, 88, 955-961.	0.5	37
121	Antibody-Mediated Rejection in Sensitized Nonhuman Primates: Modeling Human Biology. <i>American Journal of Transplantation</i> , 2016, 16, 1726-1738.	2.6	37
122	Identification of bacterial antigens in circulating immune complexes of infective endocarditis. <i>Journal of Clinical Investigation</i> , 1982, 70, 271-280.	3.9	37
123	Knowledge about transplantation tolerance gained in primates. <i>Current Opinion in Immunology</i> , 2000, 12, 552-556.	2.4	36
124	Improvement in Liver Transplant Outcomes From Older Donors. <i>Annals of Surgery</i> , 2019, 270, 333-339.	2.1	36
125	The past, present, and future of costimulation blockade in organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 2019, 24, 391-401.	0.8	36
126	B cells in transplant tolerance and rejection: friends or foes?. <i>Transplant International</i> , 2020, 33, 30-40.	0.8	36

#	ARTICLE	IF	CITATIONS
127	100 Consecutive liver transplants in infants and children: An 8-year experience. <i>Journal of Pediatric Surgery</i> , 1994, 29, 1135-1140.	0.8	35
128	Strategies for tolerance induction in nonhuman primates. <i>Current Opinion in Immunology</i> , 1998, 10, 513-517.	2.4	35
129	Alemtuzumab Induction and Recurrence of Glomerular Disease After Kidney Transplantation. <i>Transplantation</i> , 2007, 83, 1429-1434.	0.5	35
130	The role of B cells in solid organ transplantation. <i>Seminars in Immunology</i> , 2012, 24, 96-108.	2.7	35
131	Urine proteomics in kidney transplantation. <i>Transplantation Reviews</i> , 2014, 28, 15-20.	1.2	35
132	THE IMPACT OF HYPOALBUMINEMIA IN KIDNEY-PANCREAS TRANSPLANT RECIPIENTS1. <i>Transplantation</i> , 1999, 68, 72-75.	0.5	35
133	Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death. <i>Transplant International</i> , 2008, 21, 625-636.	0.8	34
134	Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. <i>Pediatric Transplantation</i> , 2008, 12, 447-455.	0.5	34
135	Unaltered Graft Survival and Intragraft Lymphocytes Infiltration in the Cardiac Allograft of Cxcr3 ^{+/+} Mouse Recipients. <i>American Journal of Transplantation</i> , 2008, 8, 1593-1603.	2.6	34
136	Hepatic enrichment and activation of myeloid dendritic cells during chronic hepatitis C virus infection. <i>Hepatology</i> , 2012, 56, 2071-2081.	3.6	34
137	One Size Does Not Fit All—Regional Variation in the Impact of the Share 35 Liver Allocation Policy. <i>American Journal of Transplantation</i> , 2016, 16, 137-142.	2.6	34
138	PROCUREMENT, PRESERVATION, AND TRANSPORT OF CADAVER KIDNEYS. <i>Surgical Clinics of North America</i> , 1998, 78, 41-54.	0.5	33
139	Surveillance of Acute Rejection in Baboon Renal Transplantation by Elevation of Interferon- γ Inducible Protein-10 and Monokine Induced by Interferon- γ in Urine. <i>Transplantation</i> , 2004, 78, 1002-1007.	0.5	33
140	Nonhuman Primate Infections after Organ Transplantation. <i>ILAR Journal</i> , 2008, 49, 209-219.	1.8	33
141	Treatment with immunotoxin. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2001, 356, 681-689.	1.8	32
142	CD28 Ligation Induces Tyrosine Phosphorylation of Pyk2 but Not Fak in Jurkat T Cells. <i>Journal of Biological Chemistry</i> , 1999, 274, 6735-6740.	1.6	31
143	The Impact of Donor Variables on the Outcome of Orthotopic Liver Transplantation for Hepatitis C. <i>Transplantation Proceedings</i> , 2008, 40, 219-223.	0.3	31
144	The Association Between Hospital Finances and Complications After Complex Abdominal Surgery. <i>Annals of Surgery</i> , 2015, 262, 273-279.	2.1	31

#	ARTICLE	IF	CITATIONS
145	Metastable tolerance in nonhuman primates and humans. <i>Transplantation</i> , 2004, 77, 936-939.	0.5	30
146	Patterns of De Novo Allo B Cells and Antibody Formation in Chronic Cardiac Allograft Rejection After Alemtuzumab Treatment. <i>American Journal of Transplantation</i> , 2012, 12, 2641-2651.	2.6	29
147	C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates. <i>Nature Communications</i> , 2021, 12, 5456.	5.8	29
148	Surgical portosystemic shunts for treatment of portal hypertensive bleeding: Outcome and effect on liver function. <i>Surgery</i> , 1999, 126, 708-713.	1.0	28
149	Utilization of pediatric donors for pancreas transplantation. <i>Transplantation Proceedings</i> , 1999, 31, 610-611.	0.3	28
150	Antibody-Mediated Rejection of the Kidney after Simultaneous Pancreas-Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 812-824.	3.0	28
151	Analysis of tumor characteristics and survival in liver transplant recipients with incidentally diagnosed hepatocellular carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2001, 5, 594-602.	0.9	27
152	Domino Liver Transplantation in Maple Syrup Urine Disease: A Case Report and Review of the Literature. <i>Transplantation Proceedings</i> , 2013, 45, 806-809.	0.3	27
153	Improved contemporary outcomes of liver transplantation for pediatric hepatoblastoma and hepatocellular carcinoma. <i>Pediatric Transplantation</i> , 2018, 22, e13305.	0.5	27
154	Translational impact of NIH-funded nonhuman primate research in transplantation. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	27
155	Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model. <i>Kidney International</i> , 2021, 99, 161-172.	2.6	27
156	INFILTRATING CELL PHENOTYPES AND PATTERNS ASSOCIATED WITH HEPATIC ALLOGRAFT REJECTION OR ACCEPTANCE. <i>Transplantation</i> , 1987, 43, 169-172.	0.5	26
157	Biologics in organ transplantation. <i>Transplant International</i> , 2012, 25, 707-719.	0.8	26
158	IMMUNOSUPPRESSIVE EFFECTS OF AN HLA CLASS I-DERIVED PEPTIDE IN A RAT CARDIAC ALLOGRAFT MODEL. <i>Transplantation</i> , 1996, 61, 1222-1228.	0.5	26
159	CD28 ligation induces rapid tyrosine phosphorylation of the linker molecule LAT in the absence of Syk and ZAP-70 tyrosine phosphorylation. <i>European Journal of Immunology</i> , 1999, 29, 2354-2359.	1.6	25
160	Percutaneous Management of Benign Biliary Strictures with Large-Bore Catheters: Comparison between Patients with and without Orthotopic Liver Transplantation. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 219-225.e1.	0.2	25
161	A Controlled, Double-Blind, Randomized Trial of Verapamil and Cyclosporine in Cadaver Renal Transplant Patients. <i>American Journal of Kidney Diseases</i> , 1993, 21, 189-195.	2.1	24
162	Enhanced De Novo Alloantibody and Antibody-Mediated Injury in Rhesus Macaques. <i>American Journal of Transplantation</i> , 2012, 12, 2395-2405.	2.6	24

#	ARTICLE	IF	CITATIONS
163	Lymphodepletional Strategies in Transplantation. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a015511-a015511.	2.9	24
164	Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients. Transplant International, 2013, 26, 592-600.	0.8	24
165	Enteric Conversion of Bladder-Drained Pancreas Allografts: Experience in 95 Patients. Transplantation Proceedings, 1998, 30, 441-442.	0.3	23
166	Contemporary Strategies and Barriers to Transplantation Tolerance. Transplantation, 2018, 102, 1213-1222.	0.5	23
167	CLINICAL HEPATITIS AFTER TRANSPLANTATION OF HEPATITIS C VIRUS-POSITIVE KIDNEYS. Transplantation, 1996, 62, 1758-1762.	0.5	23
168	THE INFLUENCE OF RS-61443 ON ANTIBODY-MEDIATED REJECTION. Transplantation, 1992, 53, 696.	0.5	22
169	Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times. Journal of Surgical Oncology, 2014, 109, 533-541.	0.8	22
170	Single-center experience with renal transplantation in patients with Wegener's granulomatosis. Transplant International, 1997, 10, 152-156.	0.8	20
171	Immunologic suppression mediated by genetically modified hepatocytes expressing secreted allo-MHC class I molecules. Human Immunology, 1998, 59, 415-425.	1.2	20
172	Single-Center Long-Term Analysis of Combined Liver-Lung Transplant Outcomes. Transplantation Direct, 2018, 4, e349.	0.8	20
173	Gene therapy in transplantation. Transplant Immunology, 1996, 4, 257-264.	0.6	19
174	Ureteroneocystostomy for renal transplantation. Journal of the American College of Surgeons, 1999, 188, 707-709.	0.2	19
175	Proceed with Caution: Liver Transplantation for Metastatic Neuroendocrine Tumors. Annals of Surgery, 1997, 225, 345-346.	2.1	19
176	Altered Distribution of H60 Minor H Antigen-Specific CD8 T Cells and Attenuated Chronic Vasculopathy in Minor Histocompatibility Antigen Mismatched Heart Transplantation in Cxcr3 ^{hi} /a ^{hi} Mouse Recipients. Journal of Immunology, 2007, 179, 8016-8025.	0.4	18
177	Transient CD86 Expression on Hepatitis C Virus-Specific CD8+ T Cells in Acute Infection Is Linked to Sufficient IL-2 Signaling. Journal of Immunology, 2010, 184, 2410-2422.	0.4	18
178	Rapamycin Interferes With Postdepletion Regulatory T Cell Homeostasis and Enhances DSA Formation Corrected by CTLA4-Ig. American Journal of Transplantation, 2016, 16, 2612-2623.	2.6	18
179	The Volume-outcome Relationship in Deceased Donor Kidney Transplantation and Implications for Regionalization. Annals of Surgery, 2018, 267, 1169-1172.	2.1	18
180	Primary Vascularization of the Graft Determines the Immunodominance of Murine Minor H Antigens during Organ Transplantation. Journal of Immunology, 2011, 187, 3997-4006.	0.4	17

#	ARTICLE	IF	CITATIONS
181	Determination of the Functional Status of Alloreactive T Cells by Interferon- γ Kinetics. <i>Transplantation</i> , 2006, 81, 590-598.	0.5	16
182	The Effectiveness of Locoregional Therapies versus Supportive Care in Maintaining Survival within the Milan Criteria in Patients with Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 1197-1204.	0.2	16
183	Miles to Go. <i>American Journal of Transplantation</i> , 2011, 11, 1119-1120.	2.6	16
184	Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization. <i>Frontiers in Immunology</i> , 2021, 12, 694763.	2.2	16
185	The influence of dose and dose rate of total lymphoid irradiation in the rat cardiac allograft model. <i>Radiotherapy and Oncology</i> , 1987, 9, 311-318.	0.3	15
186	Regulation of T Cell Receptor- and CD28-induced Tyrosine Phosphorylation of the Focal Adhesion Tyrosine Kinases Pyk2 and Fak by Protein Kinase C. <i>Journal of Biological Chemistry</i> , 2000, 275, 1344-1350.	1.6	14
187	Selenium-Binding Protein-1 in Smooth Muscle Cells is Downregulated in a Rhesus Monkey Model of Chronic Allograft Nephropathy. <i>American Journal of Transplantation</i> , 2005, 5, 58-67.	2.6	14
188	Development of tolerogenic strategies in the clinic. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2005, 360, 1739-1746.	1.8	14
189	Thrombalexin: Use of a Cytotoxic Anticoagulant to Reduce Thrombotic Microangiopathy in a Highly Sensitized Model of Kidney Transplantation. <i>American Journal of Transplantation</i> , 2017, 17, 2055-2064.	2.6	14
190	MULTIVARIATE ANALYSIS OF DONOR-SPECIFIC VERSUS RANDOM TRANSFUSION PROTOCOLS IN HAPLOIDENTICAL LIVING-RELATED TRANSPLANTS. <i>Transplantation</i> , 1991, 51, 382-384.	0.5	13
191	Potentiation of CD3-induced expression of the linker for activation of T cells (LAT) by the calcineurin inhibitors cyclosporin A and FK506. <i>Blood</i> , 2000, 95, 2733-2741.	0.6	13
192	Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling. <i>Transplantation</i> , 2003, 75, 1075-1077.	0.5	13
193	Impact of Leukocyte Function-Associated Antigen-1 Blockade on Endogenous Allospecific T Cells to Multiple Minor Histocompatibility Antigen Mismatched Cardiac Allograft. <i>Transplantation</i> , 2015, 99, 2485-2493.	0.5	13
194	Expanding the Donor Pool With Normothermic Ex Vivo Liver Perfusion: The Future Is Now. <i>American Journal of Transplantation</i> , 2016, 16, 3075-3076.	2.6	13
195	Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 410-420.	0.9	13
196	Piceatannol in combination with low doses of cyclosporine a prolongs kidney allograft survival in a stringent rat transplantation model. <i>Transplantation</i> , 2002, 74, 1609-1617.	0.5	12
197	Immunoregulation and Tolerance. <i>Transplantation Proceedings</i> , 2010, 42, S13-S15.	0.3	12
198	Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient. <i>Transplantation Reviews</i> , 2018, 32, 119-126.	1.2	12

#	ARTICLE	IF	CITATIONS
199	Experimental modeling of desensitization: What have we learned about preventing AMR?. American Journal of Transplantation, 2020, 20, 2-11.	2.6	12
200	Definition and Analysis of Textbook Outcome: A Novel Quality Measure in Kidney Transplantation. World Journal of Surgery, 2021, 45, 1504-1513.	0.8	12
201	Radiation therapy for renal transplant rejection refractory to pulse steroids and OKT3. International Journal of Radiation Oncology Biology Physics, 1996, 34, 1055-1059.	0.4	11
202	Two distinct forms of soluble MHC class I molecules synthesized by different mechanisms in normal rat cells in vitro. Human Immunology, 1998, 59, 404-414.	1.2	11
203	An overview of the actions of cyclosporine and FK506. Transplantation Reviews, 2003, 17, 165-171.	1.2	11
204	Interleukin-15 Receptor Blockade in Non-Human Primate Kidney Transplantation. Transplantation, 2010, 89, 937-944.	0.5	11
205	Belatacept: Is There BENEFIT for Liver Transplantation Too?. American Journal of Transplantation, 2014, 14, 1717-1718.	2.6	11
206	ACTIVATION OF T LYMPHOCYTES FOR ADHESION AND CYTOKINE EXPRESSION BY TOXIN-CONJUGATED ANTI-CD3 MONOCLONAL ANTIBODIES1. Transplantation, 1999, 68, 693-698.	0.5	11
207	PRETRANSPLANT STATUS AND PATIENT SURVIVAL FOLLOWING LIVER TRANSPLANTATION. Transplantation, 1995, 60, 920-925.	0.5	10
208	CD40:CD154 interactions and allograft rejection. Current Opinion in Organ Transplantation, 2000, 5, 10-15.	0.8	10
209	Rapamycin antagonizes cyclosporin A- and tacrolimus (FK506)-mediated augmentation of linker for activation of T cell expression in T cells. International Immunology, 2003, 15, 1369-1378.	1.8	10
210	A Propensity-matched Survival Analysis: Do Simultaneous Liver-lung Transplant Recipients Need a Liver?. Transplantation, 2019, 103, 1675-1682.	0.5	10
211	Transplant research in nonhuman primates to evaluate clinically relevant immune strategies in organ transplantation. Transplantation Reviews, 2019, 33, 115-129.	1.2	10
212	INCREASED GLOMERULAR DEPOSITS OF VON WILLEBRAND FACTOR IN CHRONIC, BUT NOT ACUTE, REJECTION OF PRIMATE RENAL ALLOGRAFTS1. Transplantation, 2000, 70, 877-886.	0.5	10
213	Infiltrative Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Treated With a Single High-Dose Y90 Radioembolization and Subsequent Liver Transplantation Without a Recurrence. Transplantation Direct, 2017, 3, e206.	0.8	9
214	Improved survival in simultaneous lung-liver recipients and candidates in the modern era of lung allocation. Journal of Surgical Research, 2018, 231, 395-402.	0.8	9
215	Donor apoptotic cell-based therapy for effective inhibition of donor-specific memory T and B cells to promote long-term allograft survival in allosensitized recipients. American Journal of Transplantation, 2020, 20, 2728-2739.	2.6	9
216	GRAFT SURVIVAL IN A RHESUS RENAL TRANSPLANT MODEL AFTER IMMUNOTOXIN-MEDIATED T-CELL DEPLETION IS ENHANCED BY MYCOPHENOLATE AND STEROIDS1,2. Transplantation, 2001, 72, 581-587.	0.5	9

#	ARTICLE	IF	CITATIONS
217	Single-center experience with renal transplantation in patients with Wegener's granulomatosis. <i>Transplant International</i> , 1997, 10, 152-156.	0.8	8
218	Post-transplant lymphoproliferative disorder associated with immunosuppressive therapy for renal transplantation in rhesus macaques (<i>Macaca mulatta</i>). <i>Experimental and Toxicologic Pathology</i> , 2013, 65, 1019-1024.	2.1	8
219	Equalizing MELD Scores Over Broad Geographies Is Not the Most Efficacious Way to Allocate a Scarce Resource in a Value-based Environment. <i>Annals of Surgery</i> , 2015, 262, 220-223.	2.1	8
220	Use of Donor Serum to Prevent Passive Transfer of Hyperacute Rejection. <i>Journal of Surgical Research</i> , 1994, 57, 150-155.	0.8	7
221	Reversal of acute allograft rejection using immunotoxin. <i>Transplantation Proceedings</i> , 1998, 30, 2150-2151.	0.3	7
222	T-cell depletion as a means of achieving tolerance. <i>Current Opinion in Organ Transplantation</i> , 2000, 5, 96-102.	0.8	7
223	IL-21 Biased Alemtuzumab Induced Chronic Antibody-Mediated Rejection Is Reversed by LFA-1 Costimulation Blockade. <i>Frontiers in Immunology</i> , 2018, 9, 2323.	2.2	7
224	Point-of-Care Assessment of DCD Livers During Normothermic Machine Perfusion in a Nonhuman Primate Model. <i>Hepatology Communications</i> , 2021, 5, 1527-1542.	2.0	7
225	Measuring the Impact of Targeting FcRn-Mediated IgG Recycling on Donor-Specific Alloantibodies in a Sensitized NHP Model. <i>Frontiers in Immunology</i> , 2021, 12, 660900.	2.2	7
226	The Effect of TLI and Cyclosporine on Xenograft Survival. <i>Transplantation</i> , 1990, 50, 1082.	0.5	6
227	Human interleukin-2 and lymphoproliferative (T-helper cell) responses to soluble HLA class I antigens <i>in vitro</i> : I. Specificity for polymorphic domains 1,2. <i>Tissue Antigens</i> , 1993, 42, 35-38.	1.0	6
228	Impact of improving immunosuppressive treatment on outcome in cadaveric kidney transplantation. <i>Surgery</i> , 1996, 120, 719-724.	1.0	6
229	Modulation of alloimmunity to major histocompatibility complex class I by cotransfer of cytokine genes <i>in vivo</i> . <i>Transplant Immunology</i> , 1998, 6, 169-175.	0.6	6
230	Immunologic Risks of Combined Kidney-Pancreas Transplantation. <i>Transplantation Proceedings</i> , 1998, 30, 249-250.	0.3	6
231	From Eck's Fistula to TIPS. <i>Annals of Surgery</i> , 2003, 238, S49-S55.	2.1	6
232	Systems biological analyses reveal the hepatitis C virus (HCV)-specific regulation of hematopoietic development. <i>Hepatology</i> , 2015, 61, 843-856.	3.6	6
233	Identification and Management of Abdominal Wall Varices in Pregnancy. <i>Obstetrics and Gynecology</i> , 2018, 132, 882-887.	1.2	6
234	The impact of human leukocyte antigen donor and recipient serotyping and matching on liver transplant graft failure in primary sclerosing cholangitis, autoimmune hepatitis, and primary biliary cholangitis. <i>Clinical Transplantation</i> , 2018, 32, e13388.	0.8	6

#	ARTICLE	IF	CITATIONS
235	IMMUNOTOXIN FN18-CRM9 INDUCES STRONGER T CELL SIGNALING THAN UNCONJUGATED MONOCLONAL ANTIBODY FN1812. <i>Transplantation</i> , 2001, 72, 496-503.	0.5	6
236	A cell-based multiplex immunoassay platform using fluorescent protein-barcoded reporter cell lines. <i>Communications Biology</i> , 2021, 4, 1338.	2.0	6
237	Irradiation for xenogeneic transplantation. <i>Radiotherapy and Oncology</i> , 1990, 18, 29-37.	0.3	5
238	Clinical trials: where are we now?. <i>Immunological Reviews</i> , 2003, 196, 237-246.	2.8	5
239	Elevation of multiple cytokines/chemokines in urine of human renal transplant recipients with acute and chronic injuries: potential usage for diagnosis and monitoring. <i>Transplantation Reviews</i> , 2006, 20, 165-171.	1.2	5
240	Outcomes in Kidney Transplantation Between Veterans Affairs and Civilian Hospitals. <i>Annals of Surgery</i> , 2020, 272, 506-510.	2.1	5
241	Optimal Immunosuppression Strategy in the Sensitized Kidney Transplant Recipient. <i>Journal of Clinical Medicine</i> , 2021, 10, 3656.	1.0	5
242	Prevention trumps treatment of antibody-mediated transplant rejection. <i>Journal of Clinical Investigation</i> , 2010, 120, 1036-1039.	3.9	5
243	Introducing thymus for promoting transplantation tolerance. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 549-556.	1.5	5
244	Harnessing the B Cell Response in Kidney Transplantation – Current State and Future Directions. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
245	Seek and You Will Find: Antibody and the Liver. <i>American Journal of Transplantation</i> , 2011, 11, 424-425.	2.6	4
246	Commentary: Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation. <i>Frontiers in Immunology</i> , 2017, 8, 1615.	2.2	4
247	Allo-Specific Humoral Responses: New Methods for Screening Donor-Specific Antibody and Characterization of HLA-Specific Memory B Cells. <i>Frontiers in Immunology</i> , 2021, 12, 705140.	2.2	4
248	Optical coherence tomography of small intestine allograft biopsies using a handheld surgical probe. <i>Journal of Biomedical Optics</i> , 2021, 26, .	1.4	4
249	Involvement of protein tyrosine phosphorylation in immunotoxin effects on T lymphocytes. <i>Transplantation Proceedings</i> , 1999, 31, 785.	0.3	3
250	Prolongation of Long-Term Kidney Graft Survival by a Simultaneous Liver Transplant: The Liver Does It, and the Heart Does It Too.. <i>Transplantation</i> , 2002, 74, 1370-1371.	0.5	3
251	Immune status assay (ISA): a noninvasive procedure for studying allograft rejection. <i>Transplant Immunology</i> , 2004, 13, 147-154.	0.6	3
252	Hepatic steatosis and liver transplantation. <i>Current Opinion in Organ Transplantation</i> , 2004, 9, 123-129.	0.8	3

#	ARTICLE	IF	CITATIONS
253	Review: chemokines in transplantation. <i>Transplantation Reviews</i> , 2007, 21, 107-118.	1.2	3
254	HLA-C and Liver Transplant Outcomes: Interpreting the Facts. <i>American Journal of Transplantation</i> , 2009, 9, 1491-1492.	2.6	3
255	Guidance for Liver Transplant Immunosuppression. <i>American Journal of Transplantation</i> , 2011, 11, 886-887.	2.6	3
256	Surgical Technique in Transplantation: How Much Does It Matter?. <i>American Journal of Transplantation</i> , 2015, 15, 2791-2792.	2.6	3
257	ANALYSIS OF REJECTION AND ATN AFTER INDUCTION WITH ATG, BASILIXIMAB AND DACLIZIMAB IN CADAVERIC KIDNEY TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1999, 67, S546.	0.5	3
258	Novel agents or strategies for immunosuppression after renal transplantation. <i>Current Opinion in Organ Transplantation</i> , 2003, 8, 172-178.	0.8	2
259	Challenging Choices. <i>Annals of Surgery</i> , 2004, 239, 160-161.	2.1	2
260	Surgical invention and commercialization. <i>Surgery</i> , 2008, 143, 175-181.	1.0	2
261	Regulating T Cell Behavior. <i>American Journal of Transplantation</i> , 2016, 16, 1949-1950.	2.6	2
262	Results of Renal Transplantation. , 2019, , 684-708.		2
263	Percutaneous Splenorenal Shunt Creation in a Patient with Chronic Portomesenteric Thrombosis. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1408-1409.	0.2	2
264	Pharmacological approaches to antibody-mediated rejection—are we getting closer?. <i>American Journal of Transplantation</i> , 2020, 20, 2637-2638.	2.6	2
265	Early Course of the Patient with a Kidney Transplant. , 2008, , 210-219.		2
266	Results of Renal Transplantation. , 2008, , 657-675.		2
267	DETECTION OF CELLS RECOGNIZING DONOR GRAFTDERIVED FIBROBLASTS IN THE BLOOD OF ALLOGRAFTREJECTING ANIMALS.. <i>Transplantation</i> , 2000, 69, S152.	0.5	1
268	IMMUNOREGULATION IN MONKEY KIDNEY ALLOGRAFT ACCEPTANCE: BYSTANDER SUPPRESSION OF DTH TRIGGERED BY DONOR ANTIGENS.. <i>Transplantation</i> , 2000, 69, S242.	0.5	1
269	Steps toward transplantation tolerance in the clinic. <i>Transplantation Proceedings</i> , 2001, 33, 3844-3845.	0.3	1
270	What's new in transplantation. <i>Journal of the American College of Surgeons</i> , 2001, 192, 366-371.	0.2	1

#	ARTICLE	IF	CITATIONS
271	How does alemtuzumab affect long-term graft and patient outcomes after deceased-donor kidney transplantation?. <i>Nature Clinical Practice Nephrology</i> , 2005, 1, 74-75.	2.0	1
272	Immunosuppression in nonhuman primates. <i>Transplantation Reviews</i> , 2006, 20, 131-138.	1.2	1
273	Elevated HbA1c in donor organs from patients without a diagnosis of diabetes portends worse liver allograft survival. <i>Clinical Transplantation</i> , 2017, 31, e13047.	0.8	1
274	Early Course of the Patient With a Kidney Transplant. , 2019, , 198-211.		1
275	Humoral Immunity Induced By Viral Infection Provides a Major Barrier To Hematopoietic Cell Transplantation. <i>Blood</i> , 2013, 122, 894-894.	0.6	1
276	Results of Renal Transplantation. , 2014, , 676-697.		1
277	Parallels between antibody-mediated rejection and ischemic kidney injury with respect to B cell activation. <i>Annals of Translational Medicine</i> , 2019, 7, S151-S151.	0.7	1
278	Antibody-Mediated Graft Rejection in Nonhuman Primate Models: Comparison of Sensitized Allotransplant and Xenotransplant Rejection. , 2020, , 157-164.		1
279	A Historical Cohort in Kidney Transplantation: 55-Year Follow-Up of 72 HLA-Identical, Donor-Recipient Pairs. <i>Journal of Clinical Medicine</i> , 2021, 10, 5505.	1.0	1
280	Long-term outcomes in simultaneous pancreas-kidney transplantation: lessons relearned. <i>Clinical Transplants</i> , 2003, , 215-20.	0.2	1
281	Letter to the editor in response to: Measuring success in pig to non-human-primate renal xenotransplantation: Systematic review and comparative outcomes analysis of 1051 life sustaining NHP renal allo- and xeno-transplants by Firl and Markmann. <i>American Journal of Transplantation</i> , 2022, 22, 1933-1934.	2.6	1
282	Immunotoxins in organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 1997, 2, 97.	0.8	0
283	Emergency Portacaval Shunts: Is Orloff Correct?. <i>HPB Surgery</i> , 1997, 10, 253-265.	2.2	0
284	EARLY RESULTS IN THE USE OF THYMOGLOBULIN AND SIMULECT AS INDUCTION THERAPY IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS.. <i>Transplantation</i> , 2000, 69, S160.	0.5	0
285	Alemtuzumab and tolerance: the university of wisconsin experience. <i>Transplantation Reviews</i> , 2003, 17, S26-S28.	1.2	0
286	Involvement of linker for activation of T cells in the costimulatory signaling pathways. <i>Transplantation Proceedings</i> , 2003, 35, 553-554.	0.3	0
287	Mycophenolate mofetil: what is the evidence that it decreases chronic rejection?. <i>Current Opinion in Organ Transplantation</i> , 2003, 8, 313-316.	0.8	0
288	Incidental living donor nephrectomy: a unique expansion of the donor pool. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 245-246.	0.4	0

#	ARTICLE	IF	CITATIONS
289	Liver transplantation 2007: where do we go from here?. <i>Current Opinion in Organ Transplantation</i> , 2007, 12, 211-214.	0.8	0
290	Cytokine kinetics profiling in pediatric renal transplant recipients. <i>Pediatric Transplantation</i> , 2010, 14, 636-645.	0.5	0
291	Reply to Vanhove et al. <i>Transplant International</i> , 2013, 26, e26-e27.	0.8	0
292	Starting Well: Induction Immunosuppression after Organ Transplantation. <i>Transplant International</i> , 2013, 26, 661-661.	0.8	0
293	An Introduction to Pediatric Organ Transplantation. , 2014, , 1353-1356.		0
294	Transplant Clinic Management. , 2014, , 1518-1532.		0
295	Abdominal Solid Organ Transplantation Fellowship Training. , 2014, , 1562-1565.		0
296	Medical Solid Organ Transplant Fellowship Training. , 2014, , 1566-1571.		0
297	Administration of Organ Procurement and Allocation. , 2014, , 251-263.		0
298	Reply to: "Percutaneous Management of Benign Biliary Strictures: Is It Time to Focus on Reducing Procedure Invasiveness?". <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 936-937.	0.2	0
299	Portal hypertensive bleeding. , 2017, , 1218-1230.e3.		0
300	Toward Long-term Livers. <i>Annals of Surgery</i> , 2019, 269, 28-29.	2.1	0
301	Targeting Calcium Release-activated Calcium Channel Is Not Sufficient to Prevent Rejection in Nonhuman Primate Kidney Transplantation. <i>Transplantation</i> , 2020, 104, 970-980.	0.5	0
302	Kidney Transplantation and Dialysis Access. , 2001, , 1449-1462.		0
303	Costimulatory Blockade as a Therapeutic Regimen for Prolonging Allograft Survival and Inducing Tolerance: An Overview of Recent Research. , 2001, , 127-158.		0
304	Tolerance induction. , 2001, , 149-168.		0
305	Vascular Access for Dialysis, Chemotherapy, and Nutritional Support. , 2008, , 1457-1468.		0
306	Location of portosystemic shunting. , 2012, , 1146-1158.e3.		0

#	ARTICLE	IF	CITATIONS
307	Preface to the Seventh Edition. , 2014, , xi.		0
308	Early Course of the Patient withÂaÂKidney Transplant. , 2014, , 204-215.		0
309	Transjugular Intrahepatic Portosystemic Shunt for a Challenging Pregnancy. American Journal of Gastroenterology, 2020, 115, 1935-1935.	0.2	0
310	Kidney Transplantation and Dialysis Access. , 2003, , 607-615.		0
311	Another Step Toward Becoming a Transplant Community. Annals of Surgery, 2021, 273, e149-e150.	2.1	0